Wilson Disease
📧 Sign up to get email alerts when something new happens for Wilson Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-03-30FDA Approved: TRIENTINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for TRIENTINE HYDROCHLORIDE submitted by Rising Pharma Holdings, Inc.
-
CLINICAL_TRIALS trial_result · 2020-10-26Clinical Trial Update: The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
A completed clinical trial evaluating copper parameter assessment in Wilson disease participants receiving standard of care treatment; resul…
-
FDA approval · 2020-08-04FDA Approved: PENICILLAMINE — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved Dr. Reddy's Laboratories' original application for penicillamine, a chelating agent used to treat Wilson's disease and cystinur…
-
FDA approval · 2020-02-20FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved a generic version of trientine hydrochloride from Rising Pharma Holdings, Inc. for the treatment of Wilson disease.
-
FDA approval · 2019-12-23FDA Approved: PENICILLAMINE — Original Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s original application for penicillamine as a generic drug product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-23FDA Approved: PENICILLAMINE — Original Application (Endo USA, Inc.)
The FDA approved Endo USA, Inc.'s generic penicillamine. The generic is approved for the treatment of Wilson disease and rheumatoid arthriti…
-
FDA approval · 2019-09-25FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Endo USA, Inc.)
The FDA approved Endo USA, Inc.'s original application for trientine hydrochloride, a copper chelator indicated for Wilson disease.
-
FDA approval · 2019-07-03FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Dr.Reddys Laboratories Inc)
The FDA approved an original application for trientine hydrochloride (ANDA) from Dr. Reddy's Laboratories, enabling its use as a copper-chel…
-
FDA approval · 2019-05-22FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an original application for trientine hydrochloride from Novadoz Pharmaceuticals LLC, providing a generic option for Wilson dis…
-
FDA approval · 2019-01-16FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Navinta LLC)
FDA approved Navinta LLC's original application for trientine hydrochloride (a generic drug) via ANDA. This drug is used to treat Wilson dis…
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure [NA]
This clinical trial update describes the use of plasma exchange and continuous hemodiafiltration for Wilson disease-related liver failure, w…
-
FDA approval · 2018-02-07FDA Approved: TRIENTINE HYDROCHLORIDE — Original Application (Actavis Pharma, Inc.)
FDA approved the original application for trientine hydrochloride (Actavis Pharma, Inc.), making the generic product available in the U.S.
-
CLINICAL_TRIALS trial_result · 2017-08-23Clinical Trial Update: Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine [Phase 4]
Phase 4 trial assessing the long-term outcomes of trientine in Wilson disease patients who were withdrawn from d-penicillamine therapy.
-
FDA approval · 2016-01-05FDA Approved: GALZIN — Supplemental Application (Eton Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GALZIN (zinc acetate) by Eton Pharmaceuticals.
-
FDA approval · 2015-05-22FDA Approved: GALZIN — Supplemental Application (Eton Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GALZIN (zinc acetate) from Eton Pharmaceuticals, Inc.
-
FDA approval · 2015-03-03FDA Approved: SYPRINE — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for SYPRINE (trientine hydrochloride) submitted by Bausch Health US LLC.
-
CLINICAL_TRIALS trial_result · 2014-12-31Clinical Trial Update: Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis [NA]
A completed clinical trial evaluating the efficacy of Invitro-expanded allogeneic bone marrow-derived mesenchymal stem cell transplantation …
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients [Phase 1]
This completed Phase 1 clinical trial evaluated the pharmacokinetics and tolerability of a single dose of trientine dihydrochloride in patie…
-
CLINICAL_TRIALS trial_result · 2014-05-19Clinical Trial Update: Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease [NA]
Clinical trial update on single daily dose trientine as maintenance treatment for Wilson disease; study completed with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2014-05-14Clinical Trial Update: Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. [Phase 3]
A Phase 3 long-term study in Japan assessed the efficacy and safety of zinc acetate for Wilson's disease. Results have been posted.
-
FDA approval · 2013-08-01FDA Approved: GALZIN — Supplemental Application (Eton Pharmaceuticals, Inc.)
FDA approved a supplemental application for GALZIN (zinc acetate) from Eton Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2010-09-10Clinical Trial Update: Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan. [Phase 3]
A Phase 3 trial in Japan evaluating zinc acetate for Wilson's disease has completed enrollment and the study status is listed as completed.
-
CLINICAL_TRIALS trial_result · 2006-05-09Clinical Trial Update: Study of Tetrathiomolybdate in Patients With Wilson Disease [Phase 3]
A Phase 3 clinical trial studying tetrathiomolybdate in Wilson disease has completed.